TY - JOUR
TI - Sars-cov-2 infection is asymptomatic in nearly half of adults with robust anti-spike protein receptor-binding domain antibody response
AU - Tsitsilonis, O.E.
AU - Paraskevis, D.
AU - Lianidou, E.
AU - Terpos, E.
AU - Akalestos, A.
AU - Pierros, V.
AU - Kostaki, E.G.
AU - Kastritis, E.
AU - Moutsatsou, P.
AU - Politou, M.
AU - Scorilas, A.
AU - Sphicopoulos, T.
AU - Thomaidis, N.
AU - Trougakos, I.P.
AU - Tsakris, A.
AU - Voulgaris, N.
AU - Daskalaki, C.C.
AU - Evangelakou, Z.
AU - Fouki, C.
AU - Gianniou, D.D.
AU - Gumeni, S.
AU - Kostopoulos, I.V.
AU - Manola, M.S.
AU - Orologas-Stavrou, N.
AU - Panteli, C.
AU - Papanagnou, E.-D.
AU - Rousakis, P.
AU - Sklirou, A.D.
AU - Smilkou, S.
AU - Stergiopoulou, D.
AU - Tsiodras, S.
AU - Dimopoulos, M.-A.
AU - Sfikakis, P.P.
JO - Vaccine
PY - 2021
VL - 9
TODO - 3
SP - 1-12
PB - MDPI AG
SN - 0264-410X
TODO - 10.3390/vaccines9030207
TODO - coronavirus nucleocapsid protein;  coronavirus spike glycoprotein;  immunoglobulin A;  immunoglobulin G;  immunoglobulin M;  vitronectin, adult;  aged;  antibody response;  Article;  asymptomatic coronavirus disease 2019;  community transmission;  controlled study;  electrochemiluminescence immunoassay;  female;  hospitalization;  human;  humoral immunity;  major clinical study;  male;  normal human;  pandemic;  polymerase chain reaction;  protein domain;  questionnaire;  receptor binding;  sensitivity and specificity;  seroepidemiology;  seroprevalence;  Severe acute respiratory syndrome coronavirus 2
TODO - Between June and November 2020, we assessed plasma antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein in 4996 participants (aged 18–82 years, 34.5% men) from the National and Kapodistrian University of Athens. The weighted overall prevalence was 1.6% and monthly prevalence correlated with viral RNA-confirmed SARSCoV-2 infections in Greece, in the same period. Notably, 49% of seropositive cases reported no history of SARS-CoV-2 infection-related clinical symptoms and 33% were unsuspected of their previous infection. Additionally, levels of anti-SARS-CoV-2 antibodies against the spike-protein receptorbinding domain were similar between symptomatic and asymptomatic individuals, irrespective of age and gender. Using Food and Drug Administration Emergency Use Authorization-approved assays, these results support the need for such studies on pandemic evaluation and highlight the development of robust humoral immune responses even among asymptomatic individuals. The high percentage of unsuspected/asymptomatic active cases, which may contribute to community transmission for more days than that of cases who are aware and self-isolate, underscores the necessity of measures across the population for the efficient control of the pandemic. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
ER -